U.S. officials have given full approval to the Alzheimer’s drug Leqembi. The medicine has been shown to modestly slow the mind-robbing disease and its approval clears the way for Medicare and other insurance plans to begin covering the treatment.
Medicare administrator, Chiquita Brooks-LaSure, has made clear the program will immediately begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements.
Hospitals and medical clinics have also cautioned that it may take time to get people started on the drug. “We want to ensure that appropriate patients only are the ones that get this product,” said Alexander Scott, a vice president with Eisai.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
続きを読む »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
続きを読む »
Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for itU.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease
続きを読む »
New Bill Would Require Medicare to Cover 'Home Resiliency' Amid Worsening Climate Crisis“Climate justice is a matter of disability justice,' said Sen. Ed Markey. 'It's time that we guarantee that seniors and people with disabilities can safely weather the climate crisis.'
続きを読む »
Op-ed: Medicare agency limiting access to Alzheimer’s treatmentCommentary: A new treatment for Alzheimer’s disease, lecanemab, will likely receive traditional FDA approval on Thursday. Unfortunately, the Centers for Medicare & Medicaid Services is closing the door to ready access to this new treatment.
続きを読む »